MBX Biosciences Reports Q3 GAAP EPS of -$1.29 and Strong Cash Position
MBX Biosciences has announced its third-quarter financial results, reporting a GAAP earnings per share (EPS) of -$1.29. Despite the quarterly loss, the biotechnology company highlighted a robust liquidity position, noting that it holds approximately $481.6 million in cash and investments. This capital reserve is projected to provide sufficient runway to support the company's operations through 2029. The announcement comes amid ongoing investor interest following the company's participation in major healthcare conferences and recent shifts in analyst ratings.
Tickers: $MBX